Yahoo Search Búsqueda en la Web

Resultado de búsqueda

1. clinicalinfo.hiv.gov › es › drugsDolutegravir / Lamivudina - Paciente | NIH - Clinicalinfo

   clinicalinfo.hiv.gov › es › drugs

   • En caché

   Cada tableta contiene: 50 mg dolutegravir. 300 mg lamivudina. Tome Dovato según las instrucciones de su proveedor de atención de salud. No deje de tomar ninguna dosis de Dovato, no cambie la dosis ni suspenda este medicamento sin hablar primero con su proveedor de atención de salud. Tómelo solo o con alimentos.

2. www.ncbi.nlm.nih.gov › pmc › articlesDolutegravir Plus Lamivudine Two-Drug Regimen: Safety ...

   www.ncbi.nlm.nih.gov › pmc › articles

   29 de abr. de 2021 · The use of DTG-containing two-drug regimens (2DR), and, in particular, of DTG plus lamivudine (3TC), is one of the most promising solutions to the need to ease the management of HIV treatment without harming its efficacy and safety.

   • Autor: Valeria Cento, Carlo Federico Perno
   • DOI: 10.3390/diagnostics11050809

   • Publish Year: 2021
   • Publication: Diagnostics (Basel). 2021 May; 11(5): 809.

3. Imágenes

   • 
   • 
   • 
   • 
   • 

   Ver todo

4. en.wikipedia.org › wiki › DolutegravirDolutegravir/lamivudine/tenofovir - Wikipedia

   en.wikipedia.org › wiki › Dolutegravir

   • En caché

   Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil.

5. pubmed.ncbi.nlm.nih.gov › 35079789Efficacy and Safety of Switching to Dolutegravir/Lamivudine ...

   pubmed.ncbi.nlm.nih.gov › 35079789

   29 de sept. de 2022 · Switching to DTG/3TC demonstrated noninferior and durable efficacy compared with continuing TAF-based regimens in treatment-experienced adults with HIV-1, with good safety and tolerability, and no resistance through 144 weeks.

6. pubmed.ncbi.nlm.nih.gov › 34115650Dolutegravir/lamivudine as a first-line regimen in a test-and ...

   pubmed.ncbi.nlm.nih.gov › 34115650

   1 de oct. de 2021 · Objectives: Dolutegravir/lamivudine (DTG/3TC) is indicated for treatment-naive and experienced people with HIV; however, questions remain about its utility in a test-and-treat setting because of potential transmitted resistance and baseline hepatitis B virus (HBV) co-infection.

   • Autor: Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson Wurapa, Moti Ramgopal, Pete...

   • Publish Year: 2021

7. www.ncbi.nlm.nih.gov › pmc › articlesHIV Treatment with the Two-Drug Regimen Dolutegravir Plus ...

   www.ncbi.nlm.nih.gov › pmc › articles

   24 de ago. de 2021 · The two-drug regimen dolutegravir plus lamivudine demonstrated durable efficacy for up to 3 years in phase III studies and a high barrier to resistance in treatment-naive and virologically suppressed people with HIV (PWH).

8. www.ncbi.nlm.nih.gov › pmc › articlesDolutegravir And Lamivudine Combination For The Treatment Of ...

   www.ncbi.nlm.nih.gov › pmc › articles

   23 de oct. de 2019 · The first-ever 2-drug regimen approved for the treatment of HIV-1 infection for treatment-naive people living with HIV (PLWH), consisting of the integrase inhibitor dolutegravir (DTG) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (3TC), is reviewed in this paper.